The Role of Molecular Testing in the Treatment of AML

icon

Other Resources

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, tells us about his study investigating onvansertib in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukemia (AML)

Published:11 October 2019

The published content on this page is not directed by any sponsors and is at the sole discretion of Caribou Publishing and the OBR editorial staff.

© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.